NeuroVive Pharmaceutical AB and Yungjin Pharm Corporation Ltd. announced that the clinical phase I study of KL1333 has started in Korea and that the first healthy volunteer has been enrolled. The study is a double-blind, placebo-controlled, single-dose, dose-escalation phase I clinical study to investigate the pharmacokinetics and safety/tolerability of KL1333 in healthy subjects. The study is planned to encompass a total of 60 healthy volunteers and will be fully performed by Yungjin Pharm.

KL1333 is in development for the treatment of genetic mitochondrial diseases, such as MELAS and Kearns-Sayre syndrome, for which there are no current medicines.